TCB was also shown to upregulate PD1 expression on T cells and PD-L1 expression on cancer cells and T cells, and the combination of TCB with anti-PD-L1 to have a stronger anti-tumoral effect as compared to either treatment given as monotherapy (80) (Figures 2A, C). This evidence concerns the gene CD274 and cancer.